Clinical Trial Update: Phase II Evaluation of Exhaled Nitric Oxide (NO)

View source ↗

Summary

The clinical trial update reports the completion of a Phase II study evaluating exhaled nitric oxide as a biomarker in lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer | Status: COMPLETED